BioAge shows promise with new drug BGE-102 in early trial
The company expands its Phase 1 trial after early signals show BGE-102’s potential to address inflammation beyond the…
SNY & REGN’s Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved Dupixent (dupilumab) for the treatment of…
Beyfortus® (nirsevimab) now available in Malaysia to protect all infants against RSV disease
Beyfortus® (nirsevimab) is an available option designed to protect all infants – whether born full-term or pre-term, healthy…